One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: From the MG Patient Registry.

"CONFLICT OF INTEREST I.L. receives research support from the Myasthenia Gravis Foundation of America for the MG Registry, served on a medical advisory board for Alexion and received honorarium. I.A. receives research grants from the University of Alabama at Birmingham through the Myasthenia Gravis Foundation of America (MGFA), Ra Pharmaceuticals through MGFA, Alexion through MGFA, Argenx through MGFA, Catalyst through MGFA, and Verona Pharmaceutical. T.M. receives research funding from the MGFA. P.W.D. is an employee of UCB Pharma and holds stock/stock options in UCB Pharma. G.C. is employed by the University of Alabama at Birmingham and is president of Pythagoras, Inc, a private consulting company located in Birmingham, AL. G.C. serves on the Data and Safety Monitoring Boards: AstraZeneca, Avexis Pharmaceuticals, Biolinerx, Brainstorm Cell Therapeutics, Bristol Meyers Squibb/Celgene, CSL Behring, Galmed Pharmaceuticals, Mapi Pharmaceuticals, Merck, Merck/Pfizer, Opko Biologics, Neurim, Novartis, Ophazyme, Sanofi‐Aventis, Reata, Teva, VielaBio, NHLBI (protocol review committee), NICHD (OPRU oversight committee). G.C. serves on the Consulting or Advisory Boards: Antisense Therapeutics, Biodelivery Sciences International, Biogen, Genzyme, Genentech, GW Pharmaceuticals, Immunic, Klein‐Buendel, Medimmune/Viela Bio, Medday, Merck/Serono, Neurogenesis LTD, Novartis, Osmotica Pharmaceuticals, Perception Neurosciences, Recursion/Cerexis Pharmaceuticals, Regeneron, Reckover Pharmaceuticals, Roche, SAB BIotherapeutics, and TG Therapeutics."

"Funding information Myasthenia Gravis Foundation of America, Grant/Award Number: 4823‐8809‐7586.2; the Myasthenia Gravis Foundation of America"